Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

Inclusion Criteria: All of the following criteria must be met in order to be enrolled in the study: * Age ≥18 years * Life expectancy ≥6 months * Participants with Common Terminology Criteria for Adverse Events (CTCAE) Grade 0 CIPN (exception, patients with multiple myeloma treated with bortezomib, CTCAE Grade \<=1) * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 * Breast cancer only: * Breast cancer beginning treatment with paclitaxel or docetaxel with curative intent (i.e., not metastatic disease beyond regional lymph nodes) * Planned minimum of 6 cycles of chemotherapy * Lymphoma only: * Incident lymphoma initiating treatment with vincristine * Planned minimum of 4 cycles of chemotherapy * Oxaliplatin-based regimens, Stage III colorectal cancer: Total of 6 months (planned minimum of 12 cycles). May consider Stage IV with minimal metastatic confirmed with Sponsor prior to enrollment * Bortezomib use in untreated multiple myeloma: Total of 4 months (planned minimum of 9 cycles) * Written informed consent given * Enrollment must be completed prior to receiving the first dose of chemotherapy Exclusion Criteria: Patients meeting ANY of the following criteria are not eligible for participation: * Evidence of central nervous system metastases * Evidence of clinically significant peripheral neuropathy (CTCAE \>2) as defined by patient report of frequent numbness or tingling in the hands or feet * Any uncontrolled serious illness or medical condition that would impact the conduct of the current study * Previous exposure to neurotoxic chemotherapy drugs * Pre-existing neurodegenerative disease (Parkinson's, Alzheimer's, Huntington's, etc.), neuromuscular disorder (multiple sclerosis, ALS, polio, hereditary neuromuscular disease) or history of stoke or history of traumatic brain injury * General anesthesia less than one month prior to the first dose of neurotoxic chemotherapy